Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $105.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 77.54% from the stock’s current price. A […]